Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients
Aug 12, 2020
LAUSANNE, Switzerland, Aug. 13, 2020 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of compelling 3-year follow-up results from the randomized phase II study assessing the efficacy and safety of Debio 1143 in combination with chemo-radiation therapy (CRT) vs. CRT alone for the treatment of high-risk LA-SCCHN patients. This potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist with CRT showed a statistically and clinically significant improvement in Overall Survival (OS) vs. the control group, suggesting a halving of the risk of mortality (p=0.0261).
In addition, these 3-year follow-up results in 96 LA-SCCHN patients also confirm the sustainability of the promising 2-year outcomes recently published in Lancet1 by demonstrating continued, statistically significant improvements across all other major endpoints including the doubling of the progression free survival rate along with superior duration of response. The predictable and manageable safety profile observed with Debio 1143 + CRT at 2 years remained largely unchanged at year 3, keeping in mind that study treatments were administered over three 3-week cycles at study initiation.
In February of this year, the compound received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), reaffirming its potential to offer a significant benefit over the current standard of care in LA-SCCHN, responding to the high unmet need in this debilitating cancer type. Head & Neck cancer is the 6th most common cancer with a heavy impact on both the survival of high-risk patient types and on patient quality of life, including major dysfunctional impact relative to eating, breathing and talking. Debio 1143 represents one of the few new clinical advances in Head & Neck cancer, which has not seen any newly approved therapies over the last 25 years.
"This is an important step forward for Head & Neck cancer patients and the research community as this potential front-line therapy could change the way these patients are treated from the start," stated Angela Zubel, Chief Development Officer, Debiopharm. "I am very encouraged by improvement of long-term outcomes observed in our study. These results indicate that Debio 1143 in combination with CRT has the potential to prolong patient lives and achieve better control over their disease."
"These 3-year follow-up results could have major implications for high risk Head & Neck cancer patients, especially those with negative HPV status who appear to be associated with the poorest prognosis. As the compound is now advancing into phase III, we will be able to gather further evidence for this radio-chemo enhancing IAP antagonist that has the potential to become a standard-of-care treatment for radiation oncology," expressed Prof. Jean Bourhis, Department Head of Radio-Oncology at the University Hospital of Lausanne and Lead Investigator of the study.
About Debio 1143
Debio 1143 is a potential first-in-class oral antagonist of IAPs (inhibitor of apoptosis proteins), that sensitizes tumor cells to radio-chemo therapy by promoting programmed cell death and fostering anti-tumor immunity. The clinical benefit observed in LA-SCCHN patients suggests that the integration of Debio 1143 into widely used CRT regimens is a promising investigational approach over a broad range of cancer types. The compound is currently poised to enter into a Phase III, pivotal trial this September in combination with CRT in Head & Neck cancer. Over 200 patients have been treated so far in various indications and lines of treatment, showing an adequate and consistent safety profile across studies.
Debiopharm's commitment to cancer patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton
Communication Manager
[email protected]
Tel: +41 (0)21 321 01 11
SOURCE Debiopharm
Related Links
More News
China’s Exports Soar, Putting Its Trade Surplus on Track for a Record
China’s exports grew last month at the fastest pace in almost any month since the end of the global financial crisis.
ASML’s chip equipment sales to China soar 109% despite US export curb push
Dutch semiconductor equipment giant ASML expects China to account for about 20 per cent of its total sales this year, after seeing shipments to the market more than double during the previous quarter despite mounting US pressure for tighter export restrictions on less advanced chipmaking machinery. The company’s sales to China surged 109 per cent in the third quarter compared with the previous three months, according to financial results released on Wednesday. That took China’s share of ASML’s...
Philippine law targeting foreign agents spurs fears of free speech curbs
Philippine officials want a new anti-foreign interference law ahead of the 2028 presidential election, as a raid on a suspected online scam centre near the country’s military headquarters and reports of Chinese-linked money transfers to a company tied to Vice-President Sara Duterte-Carpio’s family fuel national security concerns. On Monday, immigration and military operatives arrested 76 foreigners at a facility in Quezon City suspected of being linked to Philippine offshore gaming operators...
AI risks could repeat China shock that cost jobs, former US commerce chief Raimondo warns
The rapid and unbridled development of artificial intelligence (AI) has the potential to disrupt the US economy in a way that is comparable to the “China shock” that displaced American workers, former US commerce secretary Gina Raimondo warns. Speaking at the Bloomberg New Economy Forum in New Delhi on Tuesday, she drew parallels between AI’s potential disruption to American jobs and the past impact of Chinese manufacturing competition on the US labour market. “In America, we’ve seen what...
Japan Protests Russia’s Detention of Journalist Accused of Spying
Tokyo summoned Russia’s ambassador after a Japanese reporter was arrested in Russia’s far east and accused of collecting military intelligence.
China approves Alibaba AI models for use in iPhone Duo and other Apple handsets
China has granted approval for Alibaba Group Holding’s artificial intelligence models to be integrated into several Apple handsets, including the new iPhone Duo, in the Chinese market, clearing a key regulatory hurdle for the long-delayed launch of Apple Intelligence in the country. Updated network access permits for the iPhone Duo, iPhone 18 Pro and several earlier Apple models from China’s Ministry of Industry and Information Technology now include three approved AI systems: Apple Intelligence...
Chinese memory giant YMTC to grow revenue 6 times faster than peers as IPO nears: report
Yangtze Memory Technologies Corporation (YMTC), China’s leading flash-memory maker, is set to grow revenue six times faster than its industry peers this year as it expands into server-related business ahead of a planned initial public offering (IPO), according to Counterpoint Research. The company’s server-related revenue was effectively zero in 2024, but could account for nearly 39 per cent of its revenue by 2028, according to the market intelligence firm on Tuesday. Much of the momentum is...
Japan farm minister submits resignation in first scandal blow for PM Takaichi
Japanese Agriculture Minister Kazuo Yana said he tendered his resignation following allegations of possible vote-buying, lining him up to become the first minister in Prime Minister Sanae Takaichi’s government to quit over a scandal. “I apologise for causing such a huge inconvenience to those involved,” Yana said to reporters after submitting his resignation on Wednesday. He said he made the move out of concern for holding up parliament and his ministerial duties. Yana declined to comment on how...
Bali tipping row: call for Indonesian tourists to pay up triggers backlash
A debate over tipping culture has erupted across the Indonesian resort island of Bali and beyond, triggered by a politician’s unfavourable comparison of domestic and foreign tourists. In a social media video, I Gusti Arya Wedakarna urged domestic tourists to “normalise giving tips in touristy places”, which he said was part of the island’s “ethics”. “Perhaps that’s the psychological reason why Balinese people are more excited about serving foreigners,” said Wedakarna, an Indonesian Regional...
Indian Protesters Describe Rough Treatment by the Police
Some of those detained accused security forces of beating them during an intense crackdown on demonstrations in India’s capital over the weekend. Police have said they followed the law.
Cloudy outlook? How haze crisis is testing Singapore’s events economy
When Daniela Cruz arrived in Singapore last week, hazy skies obscured the picture-perfect sights she had seen on social media, offering a different view of the city state from the one she had expected. The 27-year-old bank associate had travelled from Australia for the Formula One Singapore Grand Prix, but the smoky weather dampened her experience. “The buildings we saw on social media were covered in haze, and it made conditions extremely hot and humid,” she said. The haze blanketing...
The Taliban Suspend BBC Broadcasts Across Afghanistan
The Taliban government has intensified its crackdown on the press in recent months but had so far targeted Afghan news outlets.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.